Viking Therapeutics

Clinical-stage biotech. VK2735: dual GLP-1/GIP in oral and injectable formulations; VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play.